Roclanda is indicated for the reduction of IOP in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.
Promotional information from Santen for healthcare professionals only
Adverse events should be reported. For UK: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Santen UK Limited (email: medinfo@santen.co.uk or telephone: 0345 075 4863). For Ireland: Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to Santen UK Limited (email: medinfo@santen.co.uk or telephone: +353 1 695 0008).
